Ola Flink
Director/Miembro de la Junta en LIPIDOR AB .
Origen de la red de primer grado Ola Flink.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
10
| Operating Division | Investment Managers | 10 |
10
| Public Company | Miscellaneous Commercial Services | 10 |
Eribis Pharmaceuticals AB
 Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage.
2
| Private Company | Pharmaceuticals: Major | 2 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Ola Flink a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
Sopherion Therapeutics LLC
 Sopherion Therapeutics LLC BiotechnologyHealth Technology Sopherion Therapeutics LLC develops and commercializes anti-cancer therapies. The company was founded by Ronald H. Goldfarb and Salvatore Forenza in 2002 and is headquartered in Princeton, NJ. | Biotechnology | Director of Finance/CFO | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| Chalmers University of Technology | College/University | Graduate Degree Graduate Degree | |
| Royal Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Umecrine AB
 Umecrine AB BiotechnologyHealth Technology Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden. | Biotechnology | Director/Board Member Chairman | |
| Pharmacia Upjohn | Corporate Officer/Principal | ||
| KCIF Fund Management AB | Director/Board Member Chief Executive Officer Chief Executive Officer Chairman Chief Executive Officer | ||
Novozymes Biopharma Sweden AB
 Novozymes Biopharma Sweden AB BiotechnologyHealth Technology Part of Repligen Corp., Novozymes Biopharma Sweden AB operates as a contract manufacturer of biological products. The company is based in Lund, Sweden. The CEO of the Swedish company is Harald Skogman. Novozymes Biopharma Sweden was acquired by Repligen Corp. from Novozymes A/S on December 20, 2011 for $29.02 million. | Biotechnology | Corporate Officer/Principal | |
| ASARINA PHARMA AB | Pharmaceuticals: Major | Public Communications Contact Comptroller/Controller/Auditor | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| NEOS AB | Medical Specialties | Chairman Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal Chief Executive Officer Chairman Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Investment Officer Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Comptroller/Controller/Auditor | |
Palette Life Sciences AB
 Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Chief Executive Officer Director/Board Member Director/Board Member | |
| INHALATION SCIENCES SWEDEN AB | Medical Specialties | Director of Finance/CFO Chief Executive Officer Director of Finance/CFO Director/Board Member | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
Cerbios-Pharma SA
 Cerbios-Pharma SA Pharmaceuticals: MajorHealth Technology Cerbios-Pharma SA develops and manufactures pharmaceutical ingredient. Its products include drug substances and products, and animal health feed. The company was founded in 1994 and is headquartered in Barbengo – Lugano, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| KD Incentive AB | Director/Board Member Chairman Director/Board Member | ||
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| NANEXA AB | Medical Specialties | Corporate Officer/Principal | |
RespiNor AS
 RespiNor AS Electronic Equipment/InstrumentsElectronic Technology RespiNor AS operates as a medical device company. The company is headquartered in Oslo, Norway. | Electronic Equipment/Instruments | Director/Board Member | |
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Investment Managers | Founder Analyst-Equity | |
| CHORDATE MEDICAL HOLDING AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ZICCUM AB | Medical Specialties | Corporate Officer/Principal Chairman Director of Finance/CFO | |
| ECTIN RESEARCH AB | Biotechnology | Chairman Director of Finance/CFO | |
| Sumit System AB | Chief Executive Officer Chairman | ||
| Isles of Wines AB | Chief Executive Officer | ||
| Bactaviva AB | Director/Board Member | ||
| Emollivet AB | Chairman Director of Finance/CFO | ||
Summit Pharmaceuticals Europe Ltd.
 Summit Pharmaceuticals Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Corp., Summit Pharmaceuticals Europe Ltd. markets pharmaceutical intermediates and raw materials. The company is based in London, UK. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| SENSIDOSE AB | Electronic Equipment/Instruments | Comptroller/Controller/Auditor Chairman |
Estadísticas
Internacional
| Suecia | 42 |
| Estados Unidos | 4 |
| Reino Unido | 3 |
| Dinamarca | 3 |
| Suiza | 2 |
Sectorial
| Health Technology | 29 |
| Commercial Services | 8 |
| Consumer Services | 3 |
| Finance | 3 |
| Electronic Technology | 3 |
Operativa
| Director/Board Member | 149 |
| Corporate Officer/Principal | 51 |
| Chairman | 47 |
| Chief Executive Officer | 28 |
| Independent Dir/Board Member | 24 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Bo Jesper Hansen | 34 |
| Stig Lennart Hansson | 32 |
| Sten Gunnar Otto Skolling | 32 |
| Torbjørn Bjerke | 27 |
| Michael Owens | 25 |
| Gunilla Lundmark | 20 |
| Terje Kalland | 20 |
| Carl Harald Janson | 19 |
| Per Nilsson | 17 |
| Hans-Peter Torsten Ekre | 16 |
| Karl Fredrik Sjövall | 13 |
| Gunnar Casserstedt | 8 |
| Robin Wright | 8 |
| Charlotta Ekman | 8 |
| Conny Börje Bogentoft | 7 |
- Bolsa de valores
- Insiders
- Ola Flink
- Conexiones Empresas
